Intravenous Immunoglobulin (IVIg) Market Research Report - Forecast To 2027

Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), By Application (Chronic inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia, Multifocal Motor Neuropathy, Immunodeficiency diseases, Primary Humoral Immunodeficiency, Myasthenia Gravis, Guillain-Barre syndrome, Kawasaki disease, ITP and others) - Forecast to 2027

ID: MRFR/Pharma/2259-HCR | February 2021 | Region: Global | 80 pages         

Intravenous Immunoglobulin Market

Intravenous immunoglobulin market is expected to reach USD 16,564 Million at CAGR of 7.9% during the forecast period of 2022-2030


By Type IgD IgG IgE IgA IgM
By Application Guillain–Barré Syndrome Hypogammaglobulinemia Specific Antibody Deficiency Chronic Inflammatory Polyneuropathy Inflammatory Myopathies Myasthenia Gravis Idiopathic Thrombocytopenic Purpura Multifocal Motor Neuropathy

Key Players

  • Kedrion S.p.A
  • Baxter International Inc
  • OMRIX Biopharmaceuticals Ltd
  • Biotest AG
  • Hualan Biological Engineering Inc
  • Shanghai RAAS Blood Products Co
  • CSL Limited
  • Grifols
  • Guizhou Taibang Biological Products Co


  • Developing healthcare infrastructure
  • Rising healthcare expenditure
Speak to Analyst Request a Free Sample

Intravenous Immunoglobulin Market Overview:

The intravenous immunoglobulin market size is expected to grow by 6.30 % and is expected to reach USD 10,485.86 Million by 2023. Immunoglobulin defines the breaking of blood plasma that contains antibodies. It is a component in blood plasma that effectively reacts to antigen. Also, it is a complex component in action. Immunoglobulin is extracted from the human body for therapeutic and non-therapeutic purposes. It is fractioned and purified during these processes. There are different classes of Immunoglobulin. These different classes of the component are useful to treat neurological and immune disorders. Some patients may not produce an adequate number of antibodies. Through immunoglobulin, it is possible to increase antibodies. The application of intravenous immunoglobulin is wide in recent years. The study about this component is high with technological advancements. 

The use of these components in therapies is proving beneficial in the medical industry. Plenty of immunological disorders are treatable with the use of these substances. With the prevalence of immune disorders, the demand for the market is continuously surging. Higher research in the intravenous immunoglobulin (IVIG) market is enabling effective treatments for patients. The expansion of the market is happening at a rapid pace in many regions. Like natural antibodies, immunoglobulin can effectively stop foreign substances that can affect the host system. All these factors will increase the intravenous immunoglobulin (IVIG) market value to 10,485 million. 

Covid analysis

The outbreak of covid 19 is bringing plenty of challenges in global industries. Covid patient care is the crucial treatment available in the health sector. The development of vaccines is another important aspect of the health industry. The treatment for other disorders is delayed in many regions. However, few urgent treatments are available other than the covid. The research about new therapies to treat covid cases is surging. Many health care centres and institutes are researching more about other alternatives. The Intravenous immunoglobulin (ivig) market is witnessing high exposure during this period. Some researches prove that they can be effective in curing covid 19. Exceptional disease management is possible through this component. With more research in the market, the development of immunoglobulin drugs and vaccines is possible. During the pandemic period, the intravenous immunoglobulin (IVIG) market is facing few challenges. The restrictions in research and production are affecting the intravenous immunoglobulin (IVIG) market growth. However, the overall market trends remain positive suing this period.

Market dynamics 

  • Crucial market drivers 

The growth of the geriatric population is a crucial driver for the intravenous immunoglobulin (IVIG) market. The aged population is affected by most chronic illnesses. Low immunity and neurological disorders are high in the aged population. It will lead to more adoption of intravenous immunoglobulin market demand. Further, the prevalence of hemophilic patients is another driver for the market. The rising number of these patients requires effective treatment. Due to the rise of hemophilic and other disorders relating to it the market is facing immense demand. In recent years, the number of drugs developed for this condition with the Immunoglobulin component is rising.

Furthermore, developing healthcare infrastructure in many regions is favouring the Intravenous immunoglobulin (ivig) market. With the development in healthcare infrastructure, more effective developments will happen in the intravenous immunoglobulin (IVIG) market. Proper treatments and drugs enhancements will take place in the forecast period. It is a crucial driver of the market that will lead to high revenue rates. Also, alternative therapies are launched in the intravenous immunoglobulin market. Alternative therapies create more awareness about this component. Additionally, the treatment variety will attract new need users for the market. The alternative treatments increase intravenous immunoglobulin (IVIG) market growth.  

Market growth opportunities 

The prevalence of chronic inflammatory disease and hypogammaglobulinemia is expected to rise the intravenous immunoglobulin (IVIG) market growth opportunities. The growth of these diseases can lessen the production of antibodies in the patient. Due to this, the intravenous immunoglobulin component will get a high scope. The use of this component will be crucial for the treatment of these diseases. The demand for the intravenous immunoglobulin (IVIG) market will grow more in the forecast period. Moreover, the prevalence of these diseases is raising R&D funding for the market.

The research and development investments will bring plenty of development possibilities for the intravenous immunoglobulin (IVIG) market. Advanced treatment, technologies and drugs will be available in the upcoming years. The governments are allocating more expenditure for the health industry. It will lead to more developments in the intravenous immunoglobulin (IVIG) market. These growth prospects will enable market expansion for the intravenous immunoglobulin market. The awareness of the market will reach a peak in the forecast period. 

  • The market restraints 

The governmental restrictions and rules are the restraining factors of the intravenous immunoglobulin (IVIG) market. New medical drugs need to pass plenty of governmental and medical norms. With proper compliance, the drugs and products get approval. The use of IVIg products has different governmental restrictions in many regions. It can hamper the overall demand for the intravenous immunoglobulin (IVIG) market in the forecast period.

With proper practice and training these immunoglobulin products will be available for patients. In many countries the products are the first tested on patients to see its effects. Due to these processes the application of intravenous immunoglobulin products can delay. Further, it can decline the demand and expansion rate of the intravenous immunoglobulin (IVIG) market in the forecast period. 

  • The market challenges 

The risk of side effects is a significant limitation in the market. Most medical drugs have manageable side effects. However, these facts can worsen in some cases. Due to the fear of side effects, the demand for the product can decline. The IVIG products can cause side effects such as high blood pressure, cough, fever, nausea, healthcare, migraine and abdominal pain.

These side effects hinder the demand. Also, some patients hesitate to accept this product due to these effects. Further, the high cost of treatment can impede the overall growth of the market. IVIg treatments are expensive. Some patients can afford this high-cost treatment. The materials used in the IVIg product are complex. Blood samples are required in the manufacturing process. High costs will hamper the revenue rates of the market. 

  • Cumulative growth analysis 

The intravenous immunoglobulin market is witnessing a persistent growth rate. Few factors constantly propel the overall demand of the market. The prevalence of the geriatric population and chronic illness is driving demand. Further, development in health infrastructure is a profitable driver for the intravenous immunoglobulin (IVIG) market.

 Innovations and developments will lead to a high growth rate. The rise in RD spending and investments will provide more scope for the market in upcoming years. The governmental restriction is a factor that disturbs the intravenous immunoglobulin (IVIG) market growth. Also, side effects are a major drawback of the intravenous immunoglobulin (IVIG) market. Overall the market trend is surging in the forecast period. 

  • Value chain analysis 

North America is the largest intravenous immunoglobulin market. It holds the highest intravenous immunoglobulin market share. The number of patients requiring immunoglobulin treatment is high in this region. The advanced health infrastructure makes immunoglobulin product adoption effortless.

The rising research in this region will lead to plenty of market developments. With newer treatments, the market expansion rate is high for North America. Furthermore, the presence of U.S. intravenous immunoglobulin (IVIG) market leads to promising developments. Governmental restriction in this region is less when compared to other regions. Quick acceptance of intravenous immunoglobulin IVIg products will lead to the highest demand rate. 

Segment overview 

By application 

  • Guillain–Barré Syndrome

  • Hypogammaglobulinemia

  • Specific Antibody Deficiency

  • Chronic Inflammatory Polyneuropathy

  • Inflammatory Myopathies

  • Myasthenia Gravis

  • Idiopathic Thrombocytopenic Purpura

  • Multifocal Motor Neuropathy

By type 

  • IgD

  • IgG

  • IgE

  • IgA

  • IgM

By geography 

  • Europe 

  • North America 

  • Latin America 

  • Asia pacific 

Competitive landscape 

The competition in the Intravenous immunoglobulin (ivig) market is moderate. With a higher number of alternative treatments, the key players will increase. Market acquisitions, expansions and partnerships with pharmacies are key strategies of the competitive landscape. Increased research and development will bring a new variety of treatments and products to the market. 

Regional analysis 

The intravenous immunoglobulin IVIg market is diversified into Asia Pacific, North America, Europe and Latin America. North America will outgrow another regional market in the forecast period. The presence of key players is the crucial reason for high demand. The production facilities of intravenous immunoglobulin products are massive in North America.

 Higher production rates and revenue rates are the key aspects in North America. Asia pacific will have tremendous demand due to rising health infrastructure. It is regions will high expansion opportunities for the intravenous immunoglobulin (IVIG) market. Europe is another region with an impressive growth rate. It is a region that will have plenty of growth opportunities for the intravenous immunoglobulin market. 

The key players in the intravenous immunoglobulin (IVIG) market are 

  1. Kedrion S.p.A

  2. Baxter International Inc

  3. OMRIX Biopharmaceuticals Ltd

  4. Biotest AG

  5. Hualan Biological Engineering Inc

  6. Shanghai RAAS Blood Products Co

  7. CSL Limited

  8. Grifols

  9. Guizhou Taibang Biological Products Co

Recent developments 

  1. New production facilities of the intravenous immunoglobulin (IVIG) market are launched in Latin America. It is a region with plenty of demand for these treatments. The facility is equipped with advanced IVIg products 

Report overview 

  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments

Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 10,485.86 Million
  • 2027: Significant Value
  •   CAGR   6.30% (2016-2023)
      Base Year   2019
      Forecast Period   20202-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Application
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   ABEONA THERAPEUTICS (US), Baxter (US), BDI Pharma (US), Biotest AG.(Germany),, China Biologic Products, Inc. (China), CSL Behring (US), Grifols Inc. (Spain), Kedrion S.p.A (us), Octapharma (Switzerland), Shire (Republic of Ireland), AND others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Developing healthcare infrastructure
  • Rising healthcare expenditure

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Intravenous Immunoglobulin Market is projected to grow at a 6.30% CAGR between 2019-2027.

    North America is predicted to lead the Intravenous Immunoglobulin Market.

    Intravenous Immunoglobulin Market is predicted to touch USD 10,485.86 Million by 2027.

    Developing healthcare infrastructure and rising healthcare expenditure is boosting market growth.

    Specific strategies adopted by market players to create a foothold in the Intravenous Immunoglobulin market include extensive R&D, mergers, collaborations, and product launches.